Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07124559) titled 'A Study of Daily Rifapentine Combined With Isoniazid (1HP) for Tuberculosis Prevention in Children Less Than 13 Years of Age With and Without HIV' on Aug. 8.
Study Type: Interventional
Study Design:
Allocation: Non-Randomized. Intervention model: Sequential Assignment. Primary purpose: Prevention. Masking: None (Open Label).
Primary Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Condition:
Tuberculosis
Intervention:
Drug: Rifapentine
Drug: Isoniazid
Recruitment Status: Not recruiting
Phase: Phase 1/Phase 2
Date of First Enrollment: December 15, 2025
Target Sample Size: 144
Count...